Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.

Read all the latest news headline updates on weight loss. Get all the weight loss breaking news updates, videos, photostories and more at Business Standard.

The former Eagles center is battling ex-teammate Beau Allen in a body fat loss competition—with a Speedo punishment on the ...

Influencer Remi Bader lost more than 100 pounds in a year after undergoing a new weight-loss surgery. The Post spoke to an ...

GLP-1 drugs have revolutionised the treatment of obesity, but the very reason they are effective is also why it's vital to prioritise exercise when taking them ...

Billions of dollars in annual revenue and the health of millions of patients are at stake in a drug industry battle over who ...

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an additional 38% considered overweight. This epidemic not only impacts individual ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Hims & Hers Health, Inc. (HIMS) shares rallied 5.7% in the last trading session to close at $34.75. This move can be attributable to notable volume with a higher number of shares being traded than in ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...